Hikma To Buy Bedford, Transfer Manufacturing For U.S. Generics Injectables
This article was originally published in The Pink Sheet Daily
Ben Venue’s shuttered Ohio plant is also slated to be part of the transaction, but Hikma’s initial focus is on moving acquired assets into its production facilities, even though the Jordan-based firm expects only limited revenue from them over the next two years.
You may also be interested in...
Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.